UNITED ~~STATESSECURITIES AND~~ ~~EXCHANGE~~STATES COMMISSIONWashington, D.C. 20549FORM 8-KCURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934Date of Report (Date of earliest event reported): May 12, 2017IASIS HEALTHCARE LLC(Exact name of registrant as specified in its charter)

Delaware		333-117362		20-1150104
(State or other jurisdiction of organization)		(Commission File Number)		(IRS Employer Identification No.)

SECURITIES AND EXCHANGE COMMISSION

117 Seaboard Lane, Building E Franklin, Tennessee		37067
(Address of principal executive offices)		(Zip Code)

WASHINGTON, DC 20549

~~Registrant’s~~FORM ~~telephone number, including area code: (615) 844~~8-~~2747Not~~K ~~Applicable(Former name or former address, if changed since last report)~~

~~Check~~CURRENT ~~the appropriate~~REPORT ~~box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~

PURSUANT ~~⃞ Written communications~~TO ~~pursuant~~SECTION to13 ~~Rule~~OR ~~425 under the Securities Act~~ 15(~~17 CFR 230.425~~d)

~~⃞ Soliciting material~~OF ~~pursuant~~THE toSECURITIES ~~Rule~~EXCHANGE ~~14a-12~~ACT ~~under~~OF ~~the~~1934 ~~Exchange Act (17 CFR 240.14a-12)~~

~~⃞ Pre-commencement communications~~Date ~~pursuant~~of toreport ~~Rule 14d-2~~(b)Date ~~under~~of ~~the~~earliest ~~Exchange~~event ~~Act~~reported): ~~(17~~May 24, ~~CFR 240.14d-2~~2017 (bMay 18, 2017))

~~⃞ Pre-commencement communications~~IASIS ~~pursuant~~HEALTHCARE toLLC ~~Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~

(Exact Name of Registrant as Specified in Charter)


Delaware	333-117362	20-1150104
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

117 Seaboard Lane, Building E Franklin, Tennessee		37067
(Address of Principal Executive Offices)		(Zip Code)

(615) 844-2747

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company	⃞
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.	⃞

Emerging growth company ☐

~~Item~~If ~~2.02.~~an ~~Results~~emerging ofgrowth ~~Operations~~company, ~~and~~indicate ~~Financial~~by ~~Condition~~check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~The information in this Report, including the Exhibit attached hereto, is furnished pursuant to~~ Item 21.0201 ofEntry ~~this~~into ~~Form~~a ~~8-K.~~Material ~~Consequently,~~Definitive ~~it is not deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section~~Agreement. ~~It may only be incorporated by reference in another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K.~~

On May 12 18, 2017, IASIS Healthcare ~~LLC~~Corporation (the parent of IASIS Healthcare LLC) (“~~Company~~Parent”) agreed to be acquired by Steward ~~issued~~Health aCare ~~press~~System ~~release~~LLC ~~announcing~~(“Steward”) ~~its~~in ~~results~~a ~~for~~merger transaction (the ~~fiscal~~“Acquisition”). ~~second quarter~~In ~~and~~connection ~~six~~with ~~months~~Steward’s ~~ended~~financing ~~March~~for 31the Acquisition, on May 18, 2017~~. For~~, ~~information~~Parent ~~regarding~~and certain of its subsidiaries (the “Real Property Sellers”) entered into a Real Property Asset Purchase Agreement (the ~~results~~“APA”) with affiliates of Medical Properties Trust, ~~reference~~Inc. is(“MPT”). ~~made~~Pursuant to the ~~press~~APA, ~~release~~immediately ~~dated~~prior ~~May~~to ~~12,~~closing ~~2017~~of the Acquisition, the Real Property Sellers will sell (the “Real Property Sale” and, ~~certain~~together ~~supplemental~~with ~~financial~~the ~~information~~Acquisition, ~~which~~the ~~are~~“Transactions”) ~~attached hereto~~to asMPT ~~Exhibit~~substantially 99all of the hospital real estate of Parent and its subsidiaries.1 The Acquisition (and ~~incorporated~~Real ~~herein~~Property Sale) byare ~~reference~~subject to regulatory and other customary approvals and conditions. Closing of the Transactions is expected to occur in the third calendar quarter of 2017.

~~The~~Item ~~press release contains non-GAAP financial measures~~7. ~~For~~01 ~~purposes of~~ Regulation G,FD a non-GAAP financial measure is a numerical measure of a registrant’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statement of income, balance sheet or statement of cash flows (or equivalent statements) of the issuer or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented. In this regard, GAAP refers to generally accepted accounting principles in the United States. Pursuant to the requirements of Regulation G, the Company has provided reconciliations within the press release of the non-GAAP financial measures to the most directly comparable GAAP financial measures Disclosure

~~Adjusted~~IASIS ~~EBITDA~~Healthcare ~~and~~LLC ~~normalized adjusted EBITDA are each non-GAAP financial measures. Adjusted EBITDA represents net earnings~~ (loss) from continuing operations before net interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation, gain on disposal of assets, and management fees. Management fees represent monitoring and advisory fees paid to management companies affiliated with TPG and JLL. Normalized adjusted EBITDA represents adjusted EBITDA before losses associated with the ~~Company’s~~ Arizona health insurance marketplace exchange plan, IT conversion related costs, EHR settlements related to prior years, initial public offering, advisory and other legal and regulatory cost and costs associated with systems improvement efforts at the “Company~~’s Houston~~”) ~~operations.~~issued Management routinely calculates and communicates adjusted EBITDA and believes that it is useful to investors because it is commonly used as an analytical indicator within the healthcare industry to evaluate performance, allocate resources and measure leverage capacity and debt service ability. In addition, the Company uses adjusted EBITDA as a ~~measure~~press ofrelease ~~financial~~regarding ~~and operating performance for its business segments and on a consolidated basis and for incentive compensation purposes. In addition, management believes that~~ the ~~presentation~~ of normalized adjusted EBITDA assists investors in evaluating the Company’s ongoing operational performance by excluding the impact of certain items that the Company believes may not be reflective of underlying business performance. Neither adjusted EBITDA nor normalized adjusted EBITDA should be considered as a measure of financial performance under generally accepted accounting principlesTransactions, ~~and~~ ~~the~~which ~~items excluded from~~ such ~~measures~~press ~~are~~release ~~significant~~is ~~components in~~furnished ~~understanding~~herewith ~~and assessing financial performance. Neither adjusted EBITDA nor normalized adjusted EBITDA should be considered in isolation or~~ as anExhibit alternative to net earnings, cash flows generated by operating, investing, or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity99. Adjusted EBITDA and normalized adjusted EBITDA, as presented, differ from “adjusted EBITDA” as defined under the Company’s senior secured credit agreements and may not be comparable to similarly titled measures of other companies1. A table describing adjusted EBITDA and normalized adjusted EBITDA and reconciling net earnings (loss) from continuing operations to adjusted EBITDA and normalized adjusted EBITDA is included later in the press release in the attached Supplemental Consolidated Statements of Operations Information.

Forward-Looking Statements

Some of the statements we make in this press release are forward-looking within the meaning of the federal securities laws, which are intended to be covered by the safe harbors created thereby. Those forward-looking statements include all statements that are not historical statements of fact and those regarding the Company’s intent, belief or expectations including, but not limited to, future financial and operating results the Company’s ability to consummate the Transactions, the Company’s plans, objectives, expectations and other statements that are not historical facts. Forward-looking statements involve known and unknown risks and uncertainties that may cause actual results in future periods to differ materially from those anticipated in the forward-looking statements. Important risks and uncertainties include that the Transactions remain subject to regulatory approvals, closing conditions and other terms and conditions contained within the definitive agreements for the Transactions, which may result in failure to close the Transactions in the timeframe we expect or at all. These additional risk factors and uncertainties are more fully described in Part I, Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016, as filed with the Securities and Exchange Commission. Although we believe that the assumptions underlying the forward-looking statements contained in this press release are reasonable, any of these assumptions could prove to be inaccurate, and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward looking statements included herein, you should not regard the inclusion of such information as a representation by the Company or any other person that the Company’s objectives and plans will be achieved. We undertake no obligation to publicly release any revisions to any forward-looking statements contained herein to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated May 12, 2017, and supplemental financial information.


Exhibit No.		Description

99.1		Press Release dated May 19, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		~~IASIS HEALTHCARE LLC~~		IASIS HEALTHCARE LLC
		By:	/s/ John M. Doyle
Date: May 24, 2017
			John M. Doyle
				By:	/s/ John M. Doyle
			Chief Financial Officer
					John M. Doyle
Date:	May 12, 2017
					Chief Financial Officer

EXHIBIT INDEX

No.		Exhibit
Exhibit No.		Description
99.1		Press Release dated May 1219, 2017~~, and supplemental financial information~~.

Filing Compare · IASIS Healthcare LLC